Monitoring anti-Xa levels in patients with cancer-associated venous thromboembolism treated with bemiparin

Galeano‐Valle, Francisco; Pérez‐Rus, Gloria; Demelo‐Rodríguez, Pablo; Ordieres‐Ortega, Lucía; Ortega-Morán, Laura; Martín, Andrés J. Muñoz; Medina-Molina, S.; Álvarez‐Sala‐Walther, Luis Antonio; Del-Toro-Cervera, Jorge

doi:10.1007/s12094-019-02258-w

Cited by 2 publications

(3 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…35 In one of the few studies examining the relationship between therapeutic parenteral anticoagulation and anti-Xa activity in patients with VTE and cancer, as compared with patients without cancer, researchers discovered that the presence of cancer did not affect aFXa levels. 36 Therefore, further research is needed to elucidate this potential association and its clinical implications.…”

Section: Discussionmentioning

confidence: 99%

“…While there is extensive research on the association between cancer and thrombosis, particularly for VTE, studies specifically investigating the impact of cancer on anti‐Xa levels during thromboprophylaxis are relatively limited 35 . In one of the few studies examining the relationship between therapeutic parenteral anticoagulation and anti‐Xa activity in patients with VTE and cancer, as compared with patients without cancer, researchers discovered that the presence of cancer did not affect aFXa levels 36 . Therefore, further research is needed to elucidate this potential association and its clinical implications.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Monitoring anti‐Xa levels in elderly medical patients undergoing thromboprophylaxis: A prospective cohort study

Papazachariou,

Papadakis,

Malikides

et al. 2024

Geriatrics Gerontology Int

View full text Add to dashboard Cite

IntroductionGiven the rising incidence of venous thromboembolism (VTE) and insufficient thromboprophylaxis dosing evidence in certain patients, the precise monitoring of anti‐Xa (aFXa) levels is crucial. The aim of this study is to investigate the achievement of prophylactic aFXa levels in medical inpatients who were receiving parenteral anticoagulant and to evaluate the impact of various factors on aFXa levels.MethodsThis is a single‐center observational cohort study conducted on patients admitted to the Department of Internal Medicine at the University Hospital of Heraklion, Greece, from March to August 2023. These individuals received low‐molecular‐weight heparins thromboprophylaxis owing to an increased risk of VTE. Data regarding demographics, past medical history, and somatometric and laboratory findings were recorded. The established range for peak prophylactic aFXa levels was defined as 0.2–0.5 IU/mL.ResultsIn this study, we enrolled 150 individuals [91 (60.7%) women] with a mean age of 80.0 ± 14.1 years. Sixty‐two (41.4%) patients exhibited non‐prophylactic peak aFXa levels. Supratherapeutic levels were observed in all underweight patients and subtherapeutic levels in 12 of 13 obese patients in class II and III. A multivariate linear regression analysis revealed that body weight, cancer, and the Charlson Comorbidity Index (CCI) were independent factors influencing aFXa levels.ConclusionsOur study reveals a substantial portion of medical elderly inpatients on thromboprophylaxis with non‐prophylactic aFXa levels, with a notable prevalence among underweight and severely obese patients. Body weight, cancer, and CCI were identified as independent factors influencing aFXa levels, advocating for tailored thromboprophylaxis strategies. Further research is warranted to validate personalized dosing approaches and to enhance clinical decision‐making. Geriatr Gerontol Int 2024; ••: ••–••.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Monitoring anti‐Xa levels in elderly medical patients undergoing thromboprophylaxis: A prospective cohort study

Papazachariou,

Papadakis,

Malikides

et al. 2024

Geriatrics Gerontology Int

View full text Add to dashboard Cite

show abstract

“…This difference was markedly high between patients under 2 months of age and the oldest group, 6–12 years (197.0 vs. 126.0 IU/kg/day), and has been attributed to a greater volume of distribution, a faster clearance and developmental haemostatic differences [7]. Children seem to need higher doses of bemiparin in IU/kg body weight than adults in order to achieve the same anti-Xa levels [8].…”

mentioning

confidence: 99%

Optimal dosing of bemiparin for deep vein thrombosis treatment in children: a retrospective study

García‐Boyano

Caballero-Caballero²,

García³

et al. 2021

Blood Coagulation &Amp; Fibrinolysis

View full text Add to dashboard Cite

Monitoring anti-Xa levels in patients with cancer-associated venous thromboembolism treated with bemiparin

Cited by 2 publications

References 39 publications

Monitoring anti‐Xa levels in elderly medical patients undergoing thromboprophylaxis: A prospective cohort study

Monitoring anti‐Xa levels in elderly medical patients undergoing thromboprophylaxis: A prospective cohort study

Optimal dosing of bemiparin for deep vein thrombosis treatment in children: a retrospective study

Contact Info

Product

Resources

About